Phase I of RG3502 in Combination With RG1273

Phase I Clinical Study of RG3502 in Combination With RG1273 in Patients With Advanced or Recurrent HER2-Positive Breast Cancer

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221197

Enrollment

Registered

2010-08-12

Start date

2010-08-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 positive Breast Cancer

Interventions

investigational material(s) Generic name etc : RG3502 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inoperable advanced or recurrent breast cancer; HER2-positive (FISH + or IHC 3+); ECOG PS :0-2

Exclusion criteria

Exclusion criteria: Clinically significant cardiac disease; Grade 3 or higher Hypersensitivity for trastuzumab

Design outcomes

Primary

Measure	Time frame
Safety, pharmacokinetics CTCAE 4.0	—

Secondary

Measure	Time frame
Efficacy, Decreased LVEF, Anti-RG3502 antibodies and anti-RG1273 antibodies RECIST 1.0	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026